Glaukos
Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of gl
Basic Information
- Category: public company
- Founded: 2001
- Headquarters: Laguna Hills
- Website: http://www.glaukos.com
Documented Facts
- Phone: 449-123.5838 (No linked source recorded for this statement.)
- Email: glaukosmedia@powers-co.com (No linked source recorded for this statement.)
- Founded: 2001 (No linked source recorded for this statement.)
- Website: http://www.glaukos.com (No linked source recorded for this statement.)
- Headquarters: Laguna Hills (No linked source recorded for this statement.)
- Country: United States (No linked source recorded for this statement.)
- Stock ticker: Y (New) (No linked source recorded for this statement.)
- Industry (SIC): Instruments (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
Evidence and Sources
- Glaukos — Official Site (official)
- Glaukos on instagram (social)
- Glaukos on facebook (social)
- Glaukos on linkedin (social)
- GLAUKOS Corp — SEC EDGAR (reference)
Citation Guidance
Explore public company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Glaukos.
- Canonical profile: https://brandsource.ai/brands/glaukos
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/glaukos/json-ld
- Citation profile API: https://brandsource.ai/api/brands/glaukos/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of gl
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 9 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.